Intranasal COVID-19 Vaccine Candidate Launches Phase 1 Study
Gaithersburg-based Altimmune, Inc. announced that the U.S. Food and Drug Administration (FDA) had cleared the Company’s Investigational New Drug (IND) application for its Phase 1 clinical trial of AdCOVID, a novel, single-dose, intranasal COVID-19 vaccine candidate.
Altimmune expects to commence patient enrollment in the Phase 1 clinical trial in the coming week.
“We believe the deployment of intranasal vaccines like AdCOVID will be essential to a successful global response to the pandemic,” said Vipin K. Garg, President, and CEO of Altimmune, in a press release.
“FDA clearance of the IND marks an important step in developing a safe and effective vaccine designed to stimulate mucosal as well as systemic immunity following intranasal administration. Developing vaccines that can effectively prevent transmission is a growing imperative to block the spread of disease and combat the emergence of new variants. We look forward to the data from this trial in the coming weeks.”
Our Trust Standards: Medical Advisory Committee